Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

ESC 2019 | CLARIFY: Symptoms Predict Risk Only in Patients with Prior MI

The 5-year follow up of patients with chronic stable angina (or as the guidelines currently call it “chronic coronary syndrome”) indicate the risk of cardiovascular death or non-fatal MI is quite low, but risk factor control is still fairly poor. This information comes from the CLARIFY study, presented at ESC 2019 and published simultaneously in Eur Heart J.

ESC 2019 | CLARIFY: Los síntomas predicen riesgo solamente en pacientes con infarto previo

In the general population of symptomatic patients, no association was found between angina and events, but the presence of new symptoms in patients with a history of MI significantly increased the risk of a second MI or cardiovascular death.

It seems obvious to conclude that patients with a history of MI are at higher risk, but what this study brings to the table is that even when all test outcomes result normal (ECG, SPECT, etc.) these are still high-risk patients.

The CLARIFY is aligned with the new guidelines and alerts us about the risk these patients present, saying they are not as stable as they seem.


Read also: ESC 2019 | Pure: Body Mass Index Shows Low Correlation with Cardiovascular Events.


This study enrolled 32703 patients from 45 countries with coronary artery disease considered “stable”, with symptomatic myocardial ischemia or angiographic stenosis >50%. The protocol allowed the inclusion of patients with prior MI or revascularization, as long as the event had taken place over three months earlier.

More than 95% of the population was on some antiplatelet antiaggregant, more than 80% were on statins, beta-blockers and inhibitors of the conversion enzyme/angiotensin blockers.

This seems a delicate treatment of guideline-oriented goals. However, risk factor management was poor.

Only 65% reached the conventional target of 140/90 mmHg blood pressure, only 61% reached <100 mg/dl LDL and only 42% managed to control both factors simultaneously.


Read also: ESC 2019 | HOPE 4: Overcoming Obstacles to Treat Risk Factors in Developing Countries.


If we use the threshold values recommended by the guidelines, it all gets slightly worse, seeing as just 7.4% of the population reach these targets.

After 5 years, 8% of the population presented the primary end point (cardiovascular death or non-fatal MI), that is 1.7 events rate per 100 persons/year.

Original title: Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry.

Reference: Sorbets E et al. Eur Heart J. 2019; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...